The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus

被引:177
|
作者
Del Prato, S
Tiengo, A
机构
[1] Univ Pisa, Sch Med, Cattedra Malattie Metab, Sect Diabet, I-50124 Pisa, Italy
[2] Univ Padua, Sch Med, Cattedra Malattie Metab, I-35100 Padua, Italy
关键词
first-phase insulin secretion; prandial glucose; hepatic glucose production; cardiovascular risk; insulin secretagogues;
D O I
10.1002/dmrr.198
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is a heterogeneous disorder characterized by defects in insulin secretion and action. Insulin resistance is a key feature of type 2 diabetes. However, insulin resistance alone does not appear to be sufficient to cause diabetes. Longitudinal studies have shown that the development of overt hyperglycemia is associated with a decline in beta -cell secretion. In patients with impaired glucose tolerance or in the early stages of type 2 diabetes, first-phase insulin release is almost invariably lost despite the enhancement of second-phase secretion. Both animal and human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis. This effect is primarily mediated at the level of the liver, allowing prompt inhibition of endogenous glucose production (EGP) and thereby restraining the mealtime rise in plasma glucose. In type 2 diabetes, the loss of the early surge of insulin release is a precocious and quite common defect that plays a pathogenic role in postmeal hyperglycemia and one that may require specific therapeutic intervention. This becomes even more apparent if the negative impact of prandial glucose spikes is taken into consideration. Epidemiological evidence exists to indicate that 2-h postload plasma glucose levels are strongly associated with all-cause and cardiovascular mortality relative risk. Indeed the acute elevation of plasma glucose concentration triggers an array of tissue responses that may contribute to the development of diabetic complications. Considering that type 2 diabetes begins with meal-related hyperglycemia in many patients, it becomes apparent that normalization of postmeal plasma glucose levels should be the target for rational therapy and the goal in the early stages of the disease. If a primary goal of diabetes therapy is control of postmeal glucose excursion, then the regulation of glucose absorption from the gut and entry into the circulation is an important mechanism to consider. The restoration of the rapid increase in plasma insulin concentration may be quite an efficient therapeutic approach. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:164 / 174
页数:11
相关论文
共 50 条
  • [1] Use of First-phase Insulin Secretion in Early Diagnosis of Thyroid Diabetes and Type 2 Diabetes Mellitus
    Meng, Li-Heng
    Huang, Yao
    Zhou, Jia
    Liang, Xing-Huan
    Xian, Jing
    Li, Li
    Qin, Ying-Fen
    CHINESE MEDICAL JOURNAL, 2017, 130 (07) : 798 - 804
  • [2] Use of First-phase Insulin Secretion in Early Diagnosis of Thyroid Diabetes and Type 2 Diabetes Mellitus
    Meng Li-Heng
    Huang Yao
    Zhou Jia
    Liang Xing-Huan
    Xian Jing
    Li Li
    Qin Ying-Fen
    中华医学杂志英文版, 2017, 130 (07) : 798 - 804
  • [3] The first and second phase of insulin secretion in naive Chinese type 2 diabetes mellitus
    Lin, Jiunn-Diann
    Hsia, Te-Lin
    Wu, Chung-Ze
    Su, Ching-Chieh
    Ma, Wen-Ya
    Hsieh, An-Tsz
    Hsieh, Chang-Hsun
    Wang, Kun
    Chu, Yi-Min
    Pei, Dee
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (06): : 780 - 786
  • [4] First Phase Insulin Secretion and Type 2 Diabetes
    Cheng, K.
    Andrikopoulos, S.
    Gunton, J. E.
    CURRENT MOLECULAR MEDICINE, 2013, 13 (01) : 126 - 139
  • [5] Physiological importance of first-phase insulin release in elderly patients with diabetes
    Meneilly, GS
    Elahi, D
    DIABETES CARE, 1998, 21 (08) : 1326 - 1329
  • [6] Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes
    Hollingdal, M
    Sturis, J
    Gall, MA
    Damsbo, P
    Pincus, S
    Veldhuis, JD
    Porksen, N
    Schmitz, O
    Juhl, CB
    DIABETIC MEDICINE, 2005, 22 (10) : 1408 - 1413
  • [7] Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes
    Hollingdal, M
    Juhl, CB
    Sturis, J
    Gall, M
    Damsbo, P
    Veldhuis, JD
    Porksen, N
    Schmitz, O
    DIABETOLOGIA, 2002, 45 : A244 - A244
  • [8] Importance of insulin therapy in people with type 2 diabetes mellitus
    Jecht, Michael
    Doetsch, Iris
    Haeussler, Ralf-Uwe
    DIABETOLOGIE, 2024, 20 (08): : 904 - 910
  • [9] Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus
    Kahn, SE
    Montgomery, B
    Howell, W
    Ligueros-Saylan, M
    Hsu, CH
    Devineni, D
    McLeod, JF
    Horowitz, A
    Foley, JE
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12): : 5824 - 5829
  • [10] Effect of intensive insulin therapy on first-phase insulin secretion in newly diagnosed type 2 diabetic patients with a family history of the disease
    Li, Qing
    Wang, Luan
    Xiao, Lin
    Wang, Zhongchao
    Wang, Fang
    Yu, Xiaolong
    Yan, Shengli
    Wang, Yangang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (02) : 612 - 618